-
71.发明授权
公开(公告)号：EP1968542B1
公开(公告)日：2013-08-14
申请号：EP06824193.4
申请日：2006-12-18
发明人： WOO, Jong Soo , KIM, Sang Wook , YI, Hong Gi , RYU, Jae Kuk
IPC分类号： A61K9/10
CPC分类号： A61K9/143 , A61K9/145 , A61K9/2054 , A61K9/209
-
72.发明授权METHOD FOR THE PREPARATION OF D-ERYTHRO-2,2-DIFLUORO-2-DEOXY-1-OXORIBOSE DERIVATIVE 有权用于生产D-赤-2,2-二氟-2-脱氧-1-OXORIBOSEDERIVATS
公开(公告)号：EP1781677B1
公开(公告)日：2013-08-07
申请号：EP05756716.6
申请日：2005-06-23
发明人： LEE, Jaeheon , PARK, Gha-Seung, Sinjeongmaeul 1-danji 107-1003 , LEE, Moonsub , KIM, Cheol-Kyong, Sinnamusil Sinmyeong Apt 634-1003, , LEE, Jae-Chul, Kyungwonyeonlip Ra-dong 101, , CHANG, Young-Kil , LEE, Gwan-Sun
IPC分类号： C07H3/08
CPC分类号： C07H3/08
-
73.发明公开COMPLEX FORMULATION FOR PREVENTING OR TREATING OSTEOPOROSIS WHICH COMPRISES SOLID DISPERSION OF VITAMIN D OR ITS DERIVATIVE AND BISPHOSPHONATE 审中-公开复杂的公式与维生素D的固体分散体及其衍生物和双膦酸盐的预防和治疗骨质疏松
公开(公告)号：EP2091543A4
公开(公告)日：2013-07-24
申请号：EP07833880
申请日：2007-11-06
申请人： HANMI SCIENCE CO LTD
发明人： WOO JONG SOO , YI HONG GI , JIN JU NAM
CPC分类号： A61K31/592 , A61K9/1611 , A61K9/1629 , A61K9/1652 , A61K9/205 , A61K9/2054 , A61K9/2866 , A61K9/5042 , A61K47/6951 , B82Y5/00 , C08B37/0015 , C08L5/16
-
74.发明公开PHARMACEUTICAL FORMULATION IN THE FORM OF BILAYERED TABLETS COMPRISING HMG-COA REDUCTASE INHIBITOR AND IRBESARTAN 有权药物制剂片剂具有两层HMG-CoA还原酶与厄贝沙坦形式
公开(公告)号：EP2568972A2
公开(公告)日：2013-03-20
申请号：EP11780838.6
申请日：2011-05-13
发明人： KIM, Yong Il , NA, Young Jun , KIM, Min Jung , KIM, Young-Hun , PARK, Jae Hyun , WOO, Jong Soo
CPC分类号： A61K31/40 , A61K9/1611 , A61K9/1652 , A61K9/2009 , A61K9/2054 , A61K9/209 , A61K31/415 , A61K45/06 , A61K2300/00
摘要： Provided is a pharmaceutical formulation in the form of bilayered tablets consisting of a first layer containing irbesartan or pharmaceutically acceptable salts thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia.
-
75.发明公开ORAL PHARMACEUTICAL COMPOSITION COMPRISING FENOFIBRIC ACID AND AN ALKALIFYING AGENT 有权口服给药的药物组合物和非诺贝特碱化
公开(公告)号：EP2558077A2
公开(公告)日：2013-02-20
申请号：EP11769045.3
申请日：2011-04-12
发明人： JANG, Ki Young , PARK, Mijin , KIM, Kyeong Soo , KIM, Yong Il , PARK, Jae Hyun , WOO, Jong Soo
IPC分类号： A61K9/22 , A61K9/16 , A61K31/192
CPC分类号： A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K31/192
摘要： An oral pharmaceutical composition of the present invention comprising fenofibric acid or a pharmaceutically acceptable salt thereof, and 0.22 to 1 part by weight of an alkalifying agent based on 1 part by weight of fenofibric acid has improved bioavailability and a minimized absorption deviation in the gastrointestinal tract, which is useful in treating hyperlipidemia and hypertriglyceridemia.
-
76.发明公开METHOD FOR PREPARING A SITE-SPECIFIC PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE 有权PROCEDURE FOR A LOCAL特定的生理活性多肽偶联物的制备
公开(公告)号：EP2408800A4
公开(公告)日：2012-12-05
申请号：EP10753706
申请日：2010-03-18
申请人： HANMI SCIENCE CO LTD
发明人： SONG DAE HAE , SHIN JAE HEE , LEE JAE MIN , PARK YOUNG KYUNG , KWON SE CHANG , LEE GWAN SUN
CPC分类号： C07K1/1077 , A61K47/60 , C07K14/575 , C07K14/605 , C07K14/62
-
77.发明公开LIQUID FORMULATIONS FOR LONG-ACTING G-CSF CONJUGATE 有权FLUSIIGE FORMULIERUNGENFÜREIN G-CSF-KONJUGAT MIT LANGZEITWIRKUNG
公开(公告)号：EP2525787A2
公开(公告)日：2012-11-28
申请号：EP11734854.0
申请日：2011-01-18
发明人： LEE, Mi Ji , LEE, Jae Min , LEE, Byung Sun , BAE, Sung Min , KWON, Se Chang
CPC分类号： A61K9/0019 , A61K38/193 , A61K47/12 , A61K47/26 , A61K47/6813 , A61K47/6835 , C07K14/535
摘要： Disclosed is a liquid formulation which allows long-acting G-CSF conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting G-CSF conjugates.
摘要翻译： 公开了一种液体制剂，其允许具有改善的体内持续时间和稳定性的长效G-CSF缀合物在长时间储存时是稳定的。 它包括以缓冲液和甘露醇为特征的稳定剂组合物。 没有人体血清白蛋白和其他对身体有害的潜在因素，液体制剂没有对病毒感染的担忧，并保证对长效G-CSF缀合物的极好的储存稳定性。
-
78.发明公开METHOD FOR PREPARING TETRAZOLE METHANESULFONIC ACID SALTS, AND NOVEL COMPOUND USED IN SAME 有权用于生产四唑甲烷硫酸盐及采用了新的CONNECTION
公开(公告)号：EP2524916A2
公开(公告)日：2012-11-21
申请号：EP11733103.3
申请日：2011-01-14
发明人： BANG, Keuk Chan , PARK, Bum Woo , CHOI, Jong Won , LEE, Jae Chul , AN, Yong Hoon , AHN, Young Gil , KIM, Maeng Sup
IPC分类号： C07D405/14 , C07D403/02 , C07D417/12
CPC分类号： C07D417/12 , C07D403/10 , C07D405/12 , C07D405/14
摘要： According to the present invention, a method for preparing tetrazole methanesulfonic acid salts comprises an acylation reaction using a novel 4-iodine-4H-chromene-2-carbothionic acid S-benzothiazole-2-yl ester. The method of the present invention can shorten a reaction time and improve safety as compared to conventional methods, and can prepare high-purity tetrazole methanesulfonic acid salts at a high yield rate without using a column chromatography method.
摘要翻译： 。根据本发明，用于使用新的4-碘-4H-苯并吡喃-2- carbothionic酸S-苯并噻唑-2-基酯制备四唑甲磺酸盐酰化反应包括一种方法。 本发明的方法可以缩短反应时间，提高安全性与传统方法相比，能够以高收率制备率的高纯度四唑甲磺酸盐，而无需使用柱色谱法。
-
公开(公告)号：EP2717918B1
公开(公告)日：2024-02-07
申请号：EP12792243.3
申请日：2012-06-01
-
80.发明授权
公开(公告)号：EP2838549B1
公开(公告)日：2021-09-22
申请号：EP13757286.3
申请日：2013-03-08
-
-
-
-
-
-
-
-
-
搜索结果
151 条记录 (耗时 0.019 秒)
